Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.11.18 (
MAP
)
7,412
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The assembly of a collection of gene-expression signatures of the major types of B-cell non-Hodgkin's lymphoma has identified increased
T-cell leukemia/lymphoma 1A
(
TCL1
) expression in multiple lymphoma types and cases, and has enabled the investigation of the functional and clinical importance of
TCL1
expression. Specifically, Burkitt's lymphoma cases show a homogeneously strong expression of
TCL1
, whereas diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, nodal marginal zone lymphoma, and splenic marginal zone lymphoma display a striking variability in the intensity of
TCL1
staining. This was validated in two independent series. A Gene-Set Enrichment Analysis of the genes correlated with
TCL1A
expression found that variation in the level of expression of
TCL1A
was significantly associated with some of the most important gene signatures recognizing B-cell lymphoma pathogenesis and heterogeneity, such as germinal center, B-cell receptor, NF-kappaB (and its target genes), death,
MAP
kinases, TNFR1, TOLL, and IL1R. Additionally,
TCL1
expression was correlated with shorter time to treatment in chronic lymphocytic leukemia cases and shorter lymphoma-specific survival in mantle cell lymphoma series, thus indicating the clinical and biological significance of
TCL1
expression, and suggesting
TCL1A
as a potential therapeutic target.
...
PMID:TCL1A expression delineates biological and clinical variability in B-cell lymphoma. 1882 Jun 75
